Table 3.
Month | Study | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Luca et al.22 | Heuman et al.20 | Ruf et al.17 | Wong et al.19 | Londono et al.23 | Huo et al.21 | |||||||
MELD | iMELD | MELD | MELD-AS | MELD | MELD-NA | MELD | MELD-NA | MELD | MELD-NA | MELD | MESO | |
iMELD=integrated model for end-stage liver disease; MELD=model for end-stage liver disease; MELD-AS=MELD-ascites sodium | [MELD + 4.53 × (sodium <135 mEq/L × 0.1) + 4.46 × (persistent ascites × 0.1)]; MELD-NA=MELD with sodium integrated; | MESO=model for end-stage liver disease/sodium ratio. | ||||||||||
3 | 0.894 | 0.905 | 0.72 | 0.75 | 0.79 | 0.83 | 0.78 | 0.795 | ||||
6 | 0.809 | 0.863 | ||||||||||
12 | 0.69 | 0.78 | 0.75 | 0.79 | 0.77 | 0.77 |